MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Unusual Whales
The Phase III VALUE trial for EscharEx® is currently progressing, with an anticipated interim assessment and completion of enrollment by the end of the first quarter of 2027. This trial is a significant step in the development of EscharEx®, a potential medical treatment. Stay tuned for updates as we move closer to these important milestones.
